280 related articles for article (PubMed ID: 7688766)
21. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
[TBL] [Abstract][Full Text] [Related]
22. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.
McElrath MJ; Corey L; Berger D; Hoffman MC; Klucking S; Dragavon J; Peterson E; Greenberg PD
J Infect Dis; 1994 Jan; 169(1):41-7. PubMed ID: 8277196
[TBL] [Abstract][Full Text] [Related]
23. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
Graham BS; Gorse GJ; Schwartz DH; Keefer MC; McElrath MJ; Matthews TJ; Wright PF; Belshe RB; Clements ML; Dolin R
J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
[TBL] [Abstract][Full Text] [Related]
25. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
[TBL] [Abstract][Full Text] [Related]
26. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Belshe RB; Newman FK; Frey SE
Vaccine; 1992; 10(6):383-8. PubMed ID: 1534641
[TBL] [Abstract][Full Text] [Related]
27. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
[TBL] [Abstract][Full Text] [Related]
28. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
[TBL] [Abstract][Full Text] [Related]
29. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.
Clerici M; Tacket CO; Via CS; Lucey DR; Muluk SC; Zajac RA; Boswell RN; Berzofsky JA; Shearer GM
Eur J Immunol; 1991 Jun; 21(6):1345-9. PubMed ID: 1845391
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
31. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
32. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
[TBL] [Abstract][Full Text] [Related]
33. Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Patel GB; Newman FK; Mandava M; Belshe RB
Vaccine; 1995 Sep; 13(13):1170-9. PubMed ID: 8578800
[TBL] [Abstract][Full Text] [Related]
34. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
Graham BS
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
[No Abstract] [Full Text] [Related]
36. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
[TBL] [Abstract][Full Text] [Related]
37. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
38. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
39. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
[TBL] [Abstract][Full Text] [Related]
40. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]